Tweet

Vincent Rajkumar

May 28 • 11 tweets • 13 min read

@ASCO

Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology

Thread with countdown👇

@RujulParikh

#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR

Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…

@ZJU_China

#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…

@kaufman_MMdoc

#3 Important study that shows compared to other standard risk MM (hyperdiploid, trisomic MM), the t(11;14) subset of myeloma has more adverse outcomes. #ASCO22 #ASCO22VR

@kaufman_MMdoc @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…

@MalinHultcrantz

#2 Risk of Progression of Smoldering Myeloma in African American patients is lower than white patients. Other studies show that outcomes in MM are related to access to good treatments. #ASCO22 #ASCO22VR @MalinHultcrantz @szusmani @DrOlaLandgren
meetings.asco.org/abstracts-pres…

@DanaFarber

#1 Results of early versus delayed transplant strategy in the VRd and Len maintenance era. Long awaited results of DETERMINATION RCT to be presented as a plenary presentation. #ASCO22 #ASCO22VR @DanaFarber #PaulRichardson #NikhilMunshi

meetings.asco.org/abstracts-pres…

https://twitter.com/VincentRK/status/1399463938794917895

Top 5 from last year in thread below. #ASCO21 #ASCO22

https://twitter.com/VincentRK/status/1399463938794917895

@ASH_hematology

Ive been using personal hashtags for many years now.

For key myeloma & healthcare cost related tweets check out:
#MyelomaVR
#CostVR

For my picks at @ASH_hematology @ASCO etc check out:
#ASH17VR
#ASH18VR
#ASH19VR
#ASCO18VR
#ASCO19VR
#ASH19VR
#ASH20VR
#ASCO21VR
#ASH21VR

@TwitterSpaces

Will comment on new findings at #ASCO22 during the meeting. Will be interesting coz I'm going to rely on other tweets and the printed abstracts for analysis and interpretation. Not attending.

And hoping to do @TwitterSpaces with colleagues. @szusmani @SagarLonialMD

I'll comment on the Plenary abstract and my #1 pick after the abstract is posted online.

You can that the RCT is so important and such a difficult trial to pull off, that regardless of the result it's #1.

This year many oral presentations have data we have already seen before in other meetings/papers with slight updates. Some of my top picks this year are in the poster sessions. Please go by if you are attending #ASCO22 and congratulate the authors.

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @VincentRK

Vincent Rajkumar

@VincentRK

May 28

Controlling COVID until the public is well vaccinated saves a huge number of lives.

See the huge difference between cases and deaths depending on when COVID occurred. 👇👇

The point is that yes with more transmissible variants countries that controlled Covid ended up with similar total numbers of cases as the US, UK, EU. But the fact they controlled COVID well for 2 years and opened up only after the public was vaccinated meant far fewer lives lost

Clearly the fact that highly transmissible variants were able to cause a massive amount of cases in a very short time in countries that previously controlled Covid shows how bad this virus is.

Read 7 tweets

Vincent Rajkumar

@VincentRK

May 18

The high cost of prescription drugs and what we need to do about it. Why nothing ever gets done.

A full 360 of the issue using cancer drugs and insulin as examples. Check it out.
1/

2/ I'm not an enemy of Pharma. I understand the value of innovation first hand. I've led numerous clinical trials, and continue to work with Pharma on new drugs.

My interest started with the recognition that every drug in my field is priced sky high. Unsustainable.👇

3/ Prescription drug prices are generally higher in the US than in every other country. Simple drugs. Complex drugs. New drugs. Old drugs. Everything.

Read 35 tweets

Vincent Rajkumar

@VincentRK

May 12

@MayoMyeloma

The Multiple Myelomas

There are 4 main types. Our recent paper gives a rough breakdown of each. nature.com/articles/s4140… @MayoMyeloma @BloodCancerJnl

@NatRevClinOncol

The initial classification is based on non overlapping primary cytogenetic abnormalities. Patients who have both trisomies and an IgH translocation are classified based on the IgH translocation. @NatRevClinOncol nature.com/articles/s4157…

These major types of myeloma have some differences in clinical presentation and features, response to therapy, and prognosis.

Read 5 tweets

Vincent Rajkumar

@VincentRK

May 7

What caused this massive difference in COVID deaths?

Not lockdowns; not lack of democracy; not new treatments.

It was testing, contact tracing, avoiding crowds, masks, controlling new cases entering the country, leadership, clear strategy, & unified messaging to public.

In response to some of the quarries.

1) Age and obesity are not factors that affect whether someone gets Covid or not. They affect outcome if someone gets Covid. These countries controlled the number of Covid cases in their countries until omicron.

The more transmissible omicron variant did cause huge spikes in cases as it swept through just as they were relaxing precautions. But they managed to control Covid until the vast majority of the population was vaccinated, which is the strategy.

Read 6 tweets

Vincent Rajkumar

@VincentRK

May 3

I updated my slide on treatment costs in myeloma. Myeloma regimens are super expensive.
1/

The regimens are expensive because other than steroids and alkylators, literally every myeloma drug is expensive. Patients are often on continuous therapy for many years. And often need more than one drug. So you can do the math.
2/

So although myeloma is just 1% of all cancers because of continuous therapy for many years and the use of multi drug combinations, in terms of cost it's footprint is far more than 1%.

In fact a myeloma drug, Revlimid, is #2 among all drugs Medicare Part D spends money on!
3/

Read 5 tweets